{"id":22752,"date":"2022-02-03T15:18:41","date_gmt":"2022-02-03T14:18:41","guid":{"rendered":"https:\/\/kymos.com\/news\/acids-nucleics-de-perdedor-biologic-a-lider-biotecnologic\/"},"modified":"2025-08-07T09:43:28","modified_gmt":"2025-08-07T07:43:28","slug":"acids-nucleics-de-perdedor-biologic-a-lider-biotecnologic","status":"publish","type":"post","link":"https:\/\/kymos.com\/ca\/news\/acids-nucleics-de-perdedor-biologic-a-lider-biotecnologic\/","title":{"rendered":"\u00c0cids nucleics: de perdedor biol\u00f2gic a l\u00edder biotecnol\u00f2gic"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:calc( 1170px + 20px );margin-left: calc(-20px \/ 2 );margin-right: calc(-20px \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-blend:overlay;--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:10px;--awb-margin-bottom-large:0px;--awb-spacing-left-large:10px;--awb-width-medium:100%;--awb-spacing-right-medium:10px;--awb-spacing-left-medium:10px;--awb-width-small:100%;--awb-spacing-right-small:10px;--awb-spacing-left-small:10px;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\"><p><span style=\"font-size: 14pt;\">The <a href=\"https:\/\/kymos.com\/ca\/serveis\/serveis-preclinics-i-clinics\/bioanalisi-dacids-nucleics\/\" data-wpel-link=\"internal\">bioanalysis of nucleic acids<\/a>, especially in biological matrices, is one of the newest services offered by the Kymos Group and carried out at its German subsidiary Prolytic. Maria Fauth, Head of the Oligonucleotides Department, has dedicated her entire academic and corporate career to the research and analysis of nucleic acids. She and Dr. Janine Lossie from OMEICOS Therapeutics share their perspectives on this promising field:<\/span><\/p>\n<p><span style=\"font-size: 14pt;\">\u201cAlready as a student I was fascinated by oligonucleotides, especially miRNAs.\u201d Maria Fauth begins. \u201cFor a long time, the scientific community regarded them as biologically useless molecules, until it was discovered that they have crucial regulatory functions. The significance of nucleic acids has been rising in the healthcare industry ever since, and with the start of the COVID-19 outbreak, mRNA vaccines have been brought to the very forefront of public awareness.\u201d<\/span><\/p>\n<p><span style=\"font-size: 14pt;\">\u201cThis represents a great acknowledgement of our team, who has been studying and working with RNA for decades, but at the same time it represents a great challenge:\u201d Ms Fauth states. \u201cThe success of mRNA vaccines has brought a lot of attention but also made it evident that nucleotide drug research can only be performed with robust analytics. This is why we have focused our efforts on the development and validation of standardized and reproducible methods for the quantification of a large variety of nucleic acids.\u201d<\/span><\/p>\n<p><span style=\"font-size: 14pt;\">The analysis of nucleic acid-based biomarkers or therapeutic drugs calls for distinct bioanalytical approaches owing to their different concentration levels: For the quantification of therapeutic oligonucleotides, ELISA or LC-MS\/MS methods are best suited depending on the need for sensitivity. However, these technologies are insufficient for biomarkers at attomolar concentrations where real-time qPCR technology becomes the gold standard. Maria Fauth elaborates further:<\/span><\/p>\n<p><span style=\"font-size: 14pt;\">\u201cWe are very pleased to be able to offer all these methods &#8211; hybridization ELISA, LC-MS\/MS and qPCR &#8211; under GLP conditions at Prolytic. With these technologies, we are not only able to quantify biomarkers or therapeutics based on DNA and mRNA, but also other emerging therapeutic tools such as aptamers or antagomiRs, which are employed to modify gene expression and to affect disease progression. Thus, we cover a broad spectrum of oligonucleotide analysis which our customers appreciate very much&#8221; she explains with satisfaction.<\/span><\/p>\n<p><span style=\"font-size: 14pt;\">As a matter of fact, many global pharmaceutical players and small biotech innovators are increasingly interested in the research of nucleic acids. Dr. Janine Lossie, Head of <em>in-vivo <\/em>Pharmacology at OMEICOS Therapeutics and a long-standing Prolytic customer, also sees the great benefit of validated analytical methods for nucleic acids:<\/span><\/p>\n<p><span style=\"font-size: 14pt;\">&#8220;Prolytic has accompanied us through the entire development process of our first-in-class small molecule OMT-28. We were very pleased to learn that Prolytic can also measure nucleic acids under GLP, as we see the potential to use these as biomarkers for evaluating the efficacy of our drugs in the future. We are confident in Maria Fauth\u2019s team proficiency and are positive that our cooperation in this area will continue to grow.&#8221;<\/span><\/p>\n<p><span style=\"font-size: 14pt;\">The determination of nucleic acid biomarkers under GLP is currently recommended but not a mandatory requirement. Nonetheless, Maria Fauth has the firm conviction that with both the FDA and EMA paying increasing attention to nucleic acid-based biomarkers, it is only a matter of time corresponding guidelines will be introduced. Her team has prepared accordingly:<\/span><\/p>\n<p><span style=\"font-size: 14pt;\">&#8220;As we are experiencing growing demand, we have established an automated processing system for nucleic acids based on magnetic beats and installed a multiplex qPCR instrument\u201d Ms Fauth states. \u201cAs a result, we are now able to achieve much higher throughputs and prepared to meet the future needs of our customers.\u201d After this Maria Fauth ends with the following thoughts. \u201cIt is a personal delight that the scientific discipline to which I have devoted years of my career, is now going through such spectacular development. Me and my team very much appreciate the innovative spirit at Prolytic and Kymos and are very much looking forward to all those interesting projects to come.\u201d<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-size: 14pt;\">OMEICOS Therapeutics is a biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular and other diseases, associated with inflammation and mitochondrial dysfunction. Find more information on <a href=\"http:\/\/www.omeicos.com\" data-wpel-link=\"external\">www.omeicos.com<\/a> or contact on <a href=\"mailto:info@omeicos.com\" data-wpel-link=\"internal\">info@omeicos.com<\/a>.<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":6,"featured_media":15245,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[95],"tags":[62],"class_list":["post-22752","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-bioanalisi","tag-joan"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>\u00c0cids nucleics: biomarcadors o f\u00e0rmacs terap\u00e8utics | Grup Kymos<\/title>\n<meta name=\"description\" content=\"Maria Fauth, Dra. Lossie (OMEICOS) sobre biomarcadors basats en \u00e0cids nucleics i f\u00e0rmacs terap\u00e8utics. Descobreix-ne m\u00e9s!\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kymos.com\/ca\/news\/acids-nucleics-de-perdedor-biologic-a-lider-biotecnologic\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u00c0cids nucleics: biomarcadors o f\u00e0rmacs terap\u00e8utics | Grup Kymos\" \/>\n<meta property=\"og:description\" content=\"Maria Fauth, Dra. Lossie (OMEICOS) sobre biomarcadors basats en \u00e0cids nucleics i f\u00e0rmacs terap\u00e8utics. Descobreix-ne m\u00e9s!\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kymos.com\/ca\/news\/acids-nucleics-de-perdedor-biologic-a-lider-biotecnologic\/\" \/>\n<meta property=\"og:site_name\" content=\"Kymos\" \/>\n<meta property=\"article:published_time\" content=\"2022-02-03T14:18:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-07T07:43:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kymos.com\/wp-content\/uploads\/2022\/02\/2022-02-05-Nucleic-Acids_Banner2_small.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1292\" \/>\n\t<meta property=\"og:image:height\" content=\"714\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Joan Puig de Dou\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KymosGroup\" \/>\n<meta name=\"twitter:site\" content=\"@KymosGroup\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"Joan Puig de Dou\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/acids-nucleics-de-perdedor-biologic-a-lider-biotecnologic\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/acids-nucleics-de-perdedor-biologic-a-lider-biotecnologic\\\/\"},\"author\":{\"name\":\"Joan Puig de Dou\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/#\\\/schema\\\/person\\\/264c93ce9dcf43caa9d634aeafab965c\"},\"headline\":\"\u00c0cids nucleics: de perdedor biol\u00f2gic a l\u00edder biotecnol\u00f2gic\",\"datePublished\":\"2022-02-03T14:18:41+00:00\",\"dateModified\":\"2025-08-07T07:43:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/acids-nucleics-de-perdedor-biologic-a-lider-biotecnologic\\\/\"},\"wordCount\":823,\"image\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/acids-nucleics-de-perdedor-biologic-a-lider-biotecnologic\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/2022-02-05-Nucleic-Acids_Banner2_small.png\",\"keywords\":[\"joan\"],\"articleSection\":[\"Bioan\u00e0lisi\"],\"inLanguage\":\"ca\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/acids-nucleics-de-perdedor-biologic-a-lider-biotecnologic\\\/\",\"url\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/acids-nucleics-de-perdedor-biologic-a-lider-biotecnologic\\\/\",\"name\":\"\u00c0cids nucleics: biomarcadors o f\u00e0rmacs terap\u00e8utics | Grup Kymos\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/acids-nucleics-de-perdedor-biologic-a-lider-biotecnologic\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/acids-nucleics-de-perdedor-biologic-a-lider-biotecnologic\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/2022-02-05-Nucleic-Acids_Banner2_small.png\",\"datePublished\":\"2022-02-03T14:18:41+00:00\",\"dateModified\":\"2025-08-07T07:43:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/#\\\/schema\\\/person\\\/264c93ce9dcf43caa9d634aeafab965c\"},\"description\":\"Maria Fauth, Dra. Lossie (OMEICOS) sobre biomarcadors basats en \u00e0cids nucleics i f\u00e0rmacs terap\u00e8utics. Descobreix-ne m\u00e9s!\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/acids-nucleics-de-perdedor-biologic-a-lider-biotecnologic\\\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/acids-nucleics-de-perdedor-biologic-a-lider-biotecnologic\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/acids-nucleics-de-perdedor-biologic-a-lider-biotecnologic\\\/#primaryimage\",\"url\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/2022-02-05-Nucleic-Acids_Banner2_small.png\",\"contentUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/2022-02-05-Nucleic-Acids_Banner2_small.png\",\"width\":1292,\"height\":714},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/acids-nucleics-de-perdedor-biologic-a-lider-biotecnologic\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/kymos.com\\\/ca\\\/inici\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u00c0cids nucleics: de perdedor biol\u00f2gic a l\u00edder biotecnol\u00f2gic\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/#website\",\"url\":\"https:\\\/\\\/kymos.com\\\/ca\\\/\",\"name\":\"Kymos Group\",\"description\":\"Kymos Group\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/kymos.com\\\/ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ca\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/#\\\/schema\\\/person\\\/264c93ce9dcf43caa9d634aeafab965c\",\"name\":\"Joan Puig de Dou\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g\",\"caption\":\"Joan Puig de Dou\"},\"description\":\"Active in the pharmaceutical marketing for over 30 years President of CataloniaBIO&amp;HealthTech CEO and Qualified Person at Kymos Leader of Kymos team, guaranteeing a trustable, ethical and scientific correct editorial publications. Experience Joan Puig de Dou started his career at Laboratorios Menarini first as scientist later as Qualified Person and finally as Operations General Manager. 2010 he entered Kymos where he became CEO in 2015. 2022 Joan Puig de Dou was elected as president of CataloniaBio&amp;HealthTech to represent the Catalonian biotech industry nationally and internationally. Expertise Joan Puig de Dou has extensive experience in writing scientific content adopting a didactic approach that fits any reader\u2019s level of expertise. He publishes regularely on Kymos\u2019 webpage, social media and in the specialized press. Education He graduated from Universitat de Barcelona as Pharmacist and from IESE Business School\u2019s Programa Diecci\u00f3n General (PDG) Want to know him better? Read his interview in PharmaBoardrooom in January 2019 and more about his presidency of CataloniaBio at Parc Sc\u00edentific de Barcelona.\",\"url\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/author\\\/joan-puig-de-dou\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u00c0cids nucleics: biomarcadors o f\u00e0rmacs terap\u00e8utics | Grup Kymos","description":"Maria Fauth, Dra. Lossie (OMEICOS) sobre biomarcadors basats en \u00e0cids nucleics i f\u00e0rmacs terap\u00e8utics. Descobreix-ne m\u00e9s!","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kymos.com\/ca\/news\/acids-nucleics-de-perdedor-biologic-a-lider-biotecnologic\/","og_locale":"ca_ES","og_type":"article","og_title":"\u00c0cids nucleics: biomarcadors o f\u00e0rmacs terap\u00e8utics | Grup Kymos","og_description":"Maria Fauth, Dra. Lossie (OMEICOS) sobre biomarcadors basats en \u00e0cids nucleics i f\u00e0rmacs terap\u00e8utics. Descobreix-ne m\u00e9s!","og_url":"https:\/\/kymos.com\/ca\/news\/acids-nucleics-de-perdedor-biologic-a-lider-biotecnologic\/","og_site_name":"Kymos","article_published_time":"2022-02-03T14:18:41+00:00","article_modified_time":"2025-08-07T07:43:28+00:00","og_image":[{"width":1292,"height":714,"url":"https:\/\/kymos.com\/wp-content\/uploads\/2022\/02\/2022-02-05-Nucleic-Acids_Banner2_small.png","type":"image\/png"}],"author":"Joan Puig de Dou","twitter_card":"summary_large_image","twitter_creator":"@KymosGroup","twitter_site":"@KymosGroup","twitter_misc":{"Escrit per":"Joan Puig de Dou","Temps estimat de lectura":"4 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kymos.com\/ca\/news\/acids-nucleics-de-perdedor-biologic-a-lider-biotecnologic\/#article","isPartOf":{"@id":"https:\/\/kymos.com\/ca\/news\/acids-nucleics-de-perdedor-biologic-a-lider-biotecnologic\/"},"author":{"name":"Joan Puig de Dou","@id":"https:\/\/kymos.com\/ca\/#\/schema\/person\/264c93ce9dcf43caa9d634aeafab965c"},"headline":"\u00c0cids nucleics: de perdedor biol\u00f2gic a l\u00edder biotecnol\u00f2gic","datePublished":"2022-02-03T14:18:41+00:00","dateModified":"2025-08-07T07:43:28+00:00","mainEntityOfPage":{"@id":"https:\/\/kymos.com\/ca\/news\/acids-nucleics-de-perdedor-biologic-a-lider-biotecnologic\/"},"wordCount":823,"image":{"@id":"https:\/\/kymos.com\/ca\/news\/acids-nucleics-de-perdedor-biologic-a-lider-biotecnologic\/#primaryimage"},"thumbnailUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2022\/02\/2022-02-05-Nucleic-Acids_Banner2_small.png","keywords":["joan"],"articleSection":["Bioan\u00e0lisi"],"inLanguage":"ca"},{"@type":"WebPage","@id":"https:\/\/kymos.com\/ca\/news\/acids-nucleics-de-perdedor-biologic-a-lider-biotecnologic\/","url":"https:\/\/kymos.com\/ca\/news\/acids-nucleics-de-perdedor-biologic-a-lider-biotecnologic\/","name":"\u00c0cids nucleics: biomarcadors o f\u00e0rmacs terap\u00e8utics | Grup Kymos","isPartOf":{"@id":"https:\/\/kymos.com\/ca\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kymos.com\/ca\/news\/acids-nucleics-de-perdedor-biologic-a-lider-biotecnologic\/#primaryimage"},"image":{"@id":"https:\/\/kymos.com\/ca\/news\/acids-nucleics-de-perdedor-biologic-a-lider-biotecnologic\/#primaryimage"},"thumbnailUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2022\/02\/2022-02-05-Nucleic-Acids_Banner2_small.png","datePublished":"2022-02-03T14:18:41+00:00","dateModified":"2025-08-07T07:43:28+00:00","author":{"@id":"https:\/\/kymos.com\/ca\/#\/schema\/person\/264c93ce9dcf43caa9d634aeafab965c"},"description":"Maria Fauth, Dra. Lossie (OMEICOS) sobre biomarcadors basats en \u00e0cids nucleics i f\u00e0rmacs terap\u00e8utics. Descobreix-ne m\u00e9s!","breadcrumb":{"@id":"https:\/\/kymos.com\/ca\/news\/acids-nucleics-de-perdedor-biologic-a-lider-biotecnologic\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kymos.com\/ca\/news\/acids-nucleics-de-perdedor-biologic-a-lider-biotecnologic\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/kymos.com\/ca\/news\/acids-nucleics-de-perdedor-biologic-a-lider-biotecnologic\/#primaryimage","url":"https:\/\/kymos.com\/wp-content\/uploads\/2022\/02\/2022-02-05-Nucleic-Acids_Banner2_small.png","contentUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2022\/02\/2022-02-05-Nucleic-Acids_Banner2_small.png","width":1292,"height":714},{"@type":"BreadcrumbList","@id":"https:\/\/kymos.com\/ca\/news\/acids-nucleics-de-perdedor-biologic-a-lider-biotecnologic\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kymos.com\/ca\/inici\/"},{"@type":"ListItem","position":2,"name":"\u00c0cids nucleics: de perdedor biol\u00f2gic a l\u00edder biotecnol\u00f2gic"}]},{"@type":"WebSite","@id":"https:\/\/kymos.com\/ca\/#website","url":"https:\/\/kymos.com\/ca\/","name":"Kymos Group","description":"Kymos Group","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kymos.com\/ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ca"},{"@type":"Person","@id":"https:\/\/kymos.com\/ca\/#\/schema\/person\/264c93ce9dcf43caa9d634aeafab965c","name":"Joan Puig de Dou","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/secure.gravatar.com\/avatar\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g","caption":"Joan Puig de Dou"},"description":"Active in the pharmaceutical marketing for over 30 years President of CataloniaBIO&amp;HealthTech CEO and Qualified Person at Kymos Leader of Kymos team, guaranteeing a trustable, ethical and scientific correct editorial publications. Experience Joan Puig de Dou started his career at Laboratorios Menarini first as scientist later as Qualified Person and finally as Operations General Manager. 2010 he entered Kymos where he became CEO in 2015. 2022 Joan Puig de Dou was elected as president of CataloniaBio&amp;HealthTech to represent the Catalonian biotech industry nationally and internationally. Expertise Joan Puig de Dou has extensive experience in writing scientific content adopting a didactic approach that fits any reader\u2019s level of expertise. He publishes regularely on Kymos\u2019 webpage, social media and in the specialized press. Education He graduated from Universitat de Barcelona as Pharmacist and from IESE Business School\u2019s Programa Diecci\u00f3n General (PDG) Want to know him better? Read his interview in PharmaBoardrooom in January 2019 and more about his presidency of CataloniaBio at Parc Sc\u00edentific de Barcelona.","url":"https:\/\/kymos.com\/ca\/news\/author\/joan-puig-de-dou\/"}]}},"_links":{"self":[{"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/posts\/22752","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/comments?post=22752"}],"version-history":[{"count":0,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/posts\/22752\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/media\/15245"}],"wp:attachment":[{"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/media?parent=22752"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/categories?post=22752"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/tags?post=22752"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}